What Riluzol Mylan Treats: Main Uses and Benefits

Riluzol Mylan (riluzole) is a medicine that is commonly used to help manage the serious neurodegenerative condition, Amyotrophic Lateral Sclerosis (ALS). This is a condition where functional stability becomes affected and symptoms linked to organ-specific functional stress are prevalent.

The primary therapeutic use of Riluzol may be considered relevant for easing the symptomatic burden associated with this condition, which is characterized by periods of heightened symptoms. The medicine is indicated for the treatment of ALS as it is applied when appropriate across domains where additional symptomatic support is needed, and may assist with maintaining functional stability during symptomatic periods.

While it is generally not a cure, it plays a role in managing the overall disease burden for conditions involving episodic or fluctuating manifestations. It is commonly used when symptoms intensify and supportive relief is needed. As a patient benefit, it supports general well-being during symptomatic phases and helps maintain a sense of stability when symptoms are more noticeable.

“Riluzol may be part of symptomatic management for patients diagnosed with ALS.”

Quick Fact: Applicable to Symptoms that Interfere with Daily Functioning

Regulatory References

1. Health Canada overview for Mylan-Riluzole

Eligibility Scope

Populations for whom use is allowed (as stated in label):

• Adults and older adults diagnosed only with Amyotrophic Lateral Sclerosis (ALS).

Populations for whom use is not recommended (if applicable):

• The pediatric population (under 18), as safety and effectiveness have not been established.
• Patients with impaired renal function (due to a lack of repeated dose studies).
• Patients with any other form of motor neurone disease (other than ALS).

Populations for whom use is contraindicated:

• Patients with a history of severe hypersensitivity reactions to Riluzole or its components.
• Patients with existing hepatic disease or specific, high baseline transaminase elevations.
• Women who are pregnant or breastfeeding.

Age-related eligibility rules: The medicine is restricted to patients ge 18 years of age. Use in older adults is permitted with no age-specific dose adjustments.

Condition-specific eligibility rules: Eligibility is precluded by severe hepatic disease or evidence of liver dysfunction, such as elevated bilirubin. Use is restricted to the treatment of ALS only.

Connection to the overall eligibility profile: Official regulatory documents define a narrow eligibility profile, permitting Riluzol Mylan’s use only in the adult population with ALS, while strictly contraindicating its use based on hypersensitivity, severe hepatic compromise, pregnancy, and lactation. Use is further not recommended for populations where safety data is insufficient, such as those with impaired renal function or those under 18 years of age.

Interactions with other medicines and products

This section describes the officially documented interaction patterns for Riluzol (the active ingredient in Riluzol Mylan) as detailed in government regulatory documents.

---

Pharmacokinetic Interactions (Exposure Modification)

Riluzole is primarily cleared through the liver via the CYP1A2 enzyme. This metabolic pathway is the basis for most documented drug interactions:

• CYP1A2 Inhibitors: Co-administration with strong or moderate inhibitors, such as Ciprofloxacin or Fluvoxamine, may significantly increase Riluzole exposure, potentially raising the concentration of the medicine in the blood.
• CYP1A2 Inducers: Co-administration with inducers, such as Rifampicin or Omeprazole, may decrease Riluzole exposure, which could result in reduced effectiveness.

---

Pharmacodynamic and Substance Interactions

Interactions that increase the risk of organ-specific toxicity are also documented:

• Hepatotoxic Drugs: Concomitant use with other medications known to affect the liver (hepatotoxic drugs) may lead to an increased risk for hepatotoxicity.
• Alcohol: Consumption of alcohol may also intensify the hepatotoxic potential of Riluzole.

---

Administration and Population Constraints

• Food: A high-fat meal is documented to interfere with absorption, resulting in a reduction in the total extent of absorption (AUC) by approximately 20% and the peak blood concentration (Cmax) by approximately 45%.
• Physiological Condition: Patients with mild or moderate hepatic impairment (liver dysfunction) are documented to have increased Riluzole plasma exposure (AUC) compared to individuals with normal liver function.

Modulating Neuronal Hyperexcitability via Sodium Channel Stabilization

Riluzole's primary pharmacodynamic action involves modulating voltage-gated sodium channels ( VGSCs) on the motor neuron cell membrane. The drug acts as a non-inactivating blocker by stabilizing the channel's inactive state, which specifically reduces the persistent sodium current (I NaL). This reduction dampens the excessive electrical firing, or hyperexcitability, of motor neurons and contributes to a reduction in electrical instability within the central nervous system.

Modulation of the Glutamate Excitatory Pathway Activity

The molecule affects the central nervous system's main excitatory pathway by reducing the voltage-dependent release of the neurotransmitter glutamate from nerve endings. It further augments the function of the astrocytic Excitatory Amino Acid Transporter 2 ( EAAT2), resulting in enhanced glutamate reuptake from the synaptic cleft.

Interruption of the Excitotoxic Cascade

These combined actions reduce the overall glutamatergic drive. The key physiological consequence is the limitation of cellular calcium ions ( Ca^2+) influx, which is the final common pathway of excitotoxicity. This mechanism targets a major physiological stressor of the motor nerve cell.

Administration Guidelines for Riluzol Mylan

This section details the standardized usage instructions for Riluzole (the active ingredient in Riluzol Mylan).

---

Administration Scope

Feature	Instruction
Route of administration	Oral administration. Alternative administration via Percutaneous Endoscopic Gastrostomy (PEG) tubes is permitted for the oral suspension form.
Dosing schedule	Standard unit dose of 50 mg. Total recommended daily dose is 100 mg. Higher daily doses are not supported.
Frequency and timing	Twice daily (b.i.d.) administration, separated by a 12-hour interval.
Timing in relation to meals	Must be taken on an empty stomach. Administration is required at least 1 hour before or 2 hours after a meal.

---

Population Rules and Procedural Conditions

• Age-Group Administration Rules: The standard 100 mg daily dose is applicable to older adults (ge 70 years), but use is not recommended for the pediatric population. Use is also not recommended for patients with severe baseline liver function impairment (ALT/AST > 5x ULN).

• Missed-Dose Protocol: If a dose is missed, the instruction is to skip the missed dose. The next dose should then be taken at the next regularly scheduled time; a double dose must not be taken.

• Special Procedural Condition: The initiation of treatment is required to occur only under the supervision of a specialist physician with experience in managing motor neurone diseases.

---

These instructions define a non-titrated, fixed-dose administration protocol that requires consistent 50 mg doses taken 12 hours apart. The protocol mandates a specialist setting for treatment initiation and places a clear time-dependent constraint on administration relative to meals, formalizing the conditions under which the medication is used.

Evidence for Use in Amyotrophic Lateral Sclerosis (ALS)

The research foundation for Riluzol Mylan centers primarily on its evaluation in studies involving individuals diagnosed with Amyotrophic Lateral Sclerosis (ALS). To understand its role, researchers conducted multiple Randomized Controlled Trials (RCTs). In these studies, patients were assigned by chance to receive either the medicine or an inactive substance (placebo), so researchers could monitor differences in the measured outcomes. This type of research was applied in studies examining patient-reported experiences and monitoring overall disease patterns.

These pivotal RCTs primarily measured time-related endpoint measures and the time until the need for mechanical respiratory support. The medicine was studied for how symptoms evolved in the observed populations over defined time intervals. Follow-up was typically intermediate-term, lasting up to 12 to 18 months, though long-term data also exist from later observational research. Studies observed patterns related to these primary endpoints.

---

What Clinical Trials and Studies Examined

Beyond the primary time-related metrics, research examined what the studies measured regarding outcomes related to daily functioning. Clinical trials assessed outcomes reflecting daily functioning or activity level using specialized rating scales. Studies also monitored specific physiological indicators, such as measures of muscle strength and pulmonary function.

The findings reported how symptoms evolved in the observed populations. For the primary time-related metrics, data show patterns related to differences in measured timeframes between the group receiving the medicine and the placebo group. However, consistent patterns were not reported by researchers across the core trials regarding the outcomes related to daily functioning, muscle strength, and respiratory capacity. Research provides insight into short-term changes, but there were no consistently reported patterns related to outcomes related to daily functioning.

---

What Remains Uncertain About Riluzol Mylan Evidence

Scientific and regulatory reviews have highlighted several areas where evidence is limited or where more research is ongoing. The primary limitation noted is the measured difference for the time-related endpoint across the pivotal studies. Functional metrics related to motor ability or muscle strength were not consistently observed in the core research. Subgroup findings for patients with the condition for five years or more are uncertain, and research does not determine whether an individual will respond similarly to the group patterns observed in the trials.

Common questions about Riluzol Mylan (FAQ)

Q: What is the main reason Riluzol Mylan is prescribed?

A: According to official regulatory documents, Riluzol Mylan is indicated for the treatment of individuals diagnosed with Amyotrophic Lateral Sclerosis (ALS). This is a specific type of progressive neurodegenerative disease.

Q: Is Riluzol Mylan a cure for the condition it treats?

A: Official regulatory documents describe the condition it treats, ALS, as a progressive and fatal disorder. The drug is licensed to extend life or the time until a patient requires mechanical ventilation. The medicine is not described as a cure in official sources.

Q: How quickly does Riluzol Mylan usually start working?

A: The medicine reaches its highest concentration in the blood within approximately 60 to 90 minutes after a dose is taken. Steady blood levels, which are the intended therapeutic concentration levels, are typically reached in less than five days of continuous use.

Q: What is the difference between Riluzol Mylan and other riluzole brands?

A: Riluzol Mylan is a brand name containing the active ingredient riluzole. Like all authorized generics or brands, Riluzol Mylan is considered bioequivalent to the original reference product, meaning it is authorized to meet the same regulatory standards for effectiveness and safety.

Q: Are there specific foods or drinks to avoid while taking Riluzol Mylan?

A: Official documents advise against drinking alcohol because it may increase the risk of liver damage. Additionally, taking the medication with a high-fat meal is documented to reduce the medicine's absorption, which can result in decreased absorption and lower blood levels.

Q: Are there any long-term effects of taking Riluzol Mylan for many years?

A: Official warnings and precautions identify a need to monitor for serious risks during treatment. These risks, which can occur during long-term use, include liver injury, low white blood cell count (neutropenia), and interstitial lung disease (a serious lung condition).

Q: What are the most common reasons people stop taking Riluzol Mylan?

A: Data from clinical trials indicates the most common reasons patients in the riluzole group stopped treatment were adverse effects like nausea, abdominal pain, and constipation. Elevated ALT levels, which signify changes in the liver, were also a common reason for discontinuation.

Q: How does Riluzol Mylan influence the progression of the disease?

A: The official licensed indication for this medicine is to help extend life or the time until a patient requires mechanical ventilation (breathing support). This purpose is focused on influencing the measured time-related progression of amyotrophic lateral sclerosis (ALS).

Q: Do studies suggest Riluzol Mylan extends life?

A: Yes. The drug's licensed indication, as defined in regulatory documents, is to extend life or the time to mechanical ventilation in individuals with amyotrophic lateral sclerosis (ALS). This finding is based on data gathered from controlled clinical trials.

Q: Is Riluzol Mylan meant to improve symptoms or slow progression?

A: The licensed use is centered on slowing progression, specifically to extend life or the time to mechanical ventilation. However, studies did not consistently report strong patterns related to outcomes reflecting daily functioning or muscle strength.

Q: What parts of the body does Riluzol Mylan primarily affect?

A: The medicine's action is on the central nervous system (CNS), where it modulates nerve cell activity. Separate from the CNS effects, official safety warnings focus on potential adverse effects on the liver, the lungs, and the blood (specifically low white blood cell count).

Q: Why is Riluzol Mylan sometimes described as a neuroprotective agent?

A: Official regulatory information describes the drug's mechanism of action, which is the factual basis for this classification. Its function includes inhibiting the release of the neurotransmitter glutamate and affecting certain sodium channels within the nerve cells.

Q: How is Riluzol Mylan eliminated from the body?

A: The medicine is metabolized (processed) in the liver by the CYP1A2 enzyme. Following metabolism, the medicine is primarily eliminated from the body via the urine, which accounts for approximately 90% of the dose.

Q: Can Riluzol Mylan be taken by people who have mild kidney problems?

A: Pharmacokinetic studies did not show a significant difference in how the medicine is processed in individuals with moderate or severe kidney impairment. However, some regulatory documents advise caution and state that treatment is not recommended for patients with impaired kidney function because dedicated repeated-dose studies were not conducted in this group.

Q: Is Riluzol Mylan a type of chemotherapy drug?

A: No. Riluzol Mylan is classified as a benzothiazole and an Amyotrophic Lateral Sclerosis (ALS) Agent. It works as a glutamate antagonist, which is a type of medicine that blocks the effects of the chemical messenger glutamate.

Q: Do women who are pregnant or breastfeeding typically use Riluzol Mylan?

A: Official regulatory information generally advises against using the medicine if a woman is pregnant or breastfeeding. This precaution is based on potential risks that have been observed in studies involving animals.

Q: Does Riluzol Mylan cause weight gain or weight loss?

A: Official reports of adverse reactions list unusual weight gain or loss as a possible, but less common, effect. This information is derived from post-marketing reports and clinical trial data.

Q: Can taking Riluzol Mylan make a person more sensitive to sunlight?

A: Yes. Official adverse reaction data lists a photosensitivity reaction as an infrequent side effect that has been reported in patients taking the medicine.

Q: Why is it important to take Riluzol Mylan as directed by the healthcare provider?

A: Following the specific administration directions is important to ensure the medicine maintains stable levels in the blood and maximizes its absorption. This is necessary to support the drug concentration levels observed in clinical studies.

Q: Does Riluzol Mylan have a strong potential for addiction?

A: Official drug scheduling information indicates that Riluzole is not listed as a controlled substance under the Controlled Substances Act. This means the medicine does not carry a formal regulatory risk for abuse or addiction.

Q: Is Riluzol Mylan used to treat conditions other than ALS in some research settings?

A: Yes. While the medicine is only licensed for ALS, it has been, or is currently being, examined in research studies for potential use in other conditions. This research includes studies related to mood and anxiety disorders.

Q: Does Riluzol Mylan affect blood pressure?

A: Yes. Clinical trial data lists hypertension (high blood pressure) as a common adverse reaction. This reaction occurred more frequently in those taking the medicine compared to those in the placebo group during studies.

Q: Does Riluzol Mylan interact with common antidepressant medications?

A: Yes. The drug is known to interact with certain antidepressants, such as Fluvoxamine, which is a CYP1A2 inhibitor that may increase the medicine's blood concentration. It can also interact with certain drugs that increase the risk of CNS depression (e.g., tricyclic antidepressants).

Q: Can Riluzol Mylan cause problems with the mouth or throat?

A: Yes. Clinical trial data lists oral hypoesthesia as a common adverse reaction. Oral hypoesthesia is described as a diminished sense of feeling or numbness in the mouth.

Q: Are there specific warnings related to driving or operating machinery while on Riluzol Mylan?

A: Due to the potential risk of side effects like dizziness and somnolence (drowsiness), patient counseling information advises caution. Official warnings state that caution should be exercised when driving or operating machinery, particularly during the initial phase of treatment.

Q: Does Riluzol Mylan cause changes in mood or behavior?

A: Regulatory adverse event data includes rare reports of attempted suicide during the post-marketing period. This is considered a serious but uncommon behavioral change documented in official sources.

Q: Is Riluzol Mylan known to interact with caffeine?

A: Yes. Official information indicates the medicine's metabolism can be affected by caffeine, which is found in coffee, tea, and cola. Caffeine is classified as a CYP1A2 inhibitor that could potentially increase the concentration of the medicine in the blood.

Q: What happens if someone accidentally takes too much Riluzol Mylan?

A: Official information on overdose reports a range of symptoms. These can include drowsiness, memory loss, blueness of the skin, respiratory difficulty, and neurological effects such as seizures, uncoordinated movements, and potentially coma.

Q: Is Riluzol Mylan available in different strengths?

A: The medicine is supplied in a 50 mg tablet form. It is also available as an oral suspension with a concentration of 50 mg per 10 mL, allowing for an alternative administration method.

Storage and Disposal of Riluzol Mylan

Storage Requirements

Riluzol Mylan tablets must be stored at controlled room temperature, generally defined as between 20 C to 25 C (68 F to 77 F), with permitted brief excursions. The medication must be kept in its original container, and the container must be kept tightly closed to protect the tablets from light and moisture.

It is prohibited to refrigerate or freeze the tablets. The product must always be stored out of the sight and reach of children.

---

Disposal Instructions

Unused or expired Riluzol Mylan must not be thrown away using wastewater or household waste (trash). Disposal of the product and its packaging must be carried out in accordance with local regulations or by returning it to a pharmacist for proper pharmaceutical waste handling.